John Scholler

USPTO Granted Patents = 21 (Patent Applications = 10)

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 14)

Average Co-Inventor Count = 4.3

ph-index = 7

Forward Citations = 337(Granted Patents)

Location History:

Penn Valley, PA (US) (2016 - 2023)
Narberth, PA (US) (2016 - 2024)

Company Filing History:

21 out of 2,597

University of Pennsylvania

University of Pittsburgh

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12350334 - Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer (2025-07-08),

2. 12234274 - Use of the CD2 signaling domain in second-generation chimeric antigen receptors (2025-02-25),

3. 11958892 - Use of ICOS-based cars to enhance antitumor activity and car persistence (2024-04-16),

4. 11865167 - Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor (2024-01-09),

5. 11718685 - Compositions and methods for targeting stromal cells for the treatment of cancer (2023-08-08),

6. 11597754 - Use of the CD2 signaling domain in second-generation chimeric antigen receptors (2023-03-07),

7. 11299536 - Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer (2022-04-12),

8. 11028177 - Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells (2021-06-08),

9. 10927184 - Treatment of cancer using humanized anti-CD19 chimeric antigen receptor (2021-02-23),

10. 10800840 - Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer (2020-10-13),

11. 10577407 - Use of ICOS-based CARS to enhance antitumor activity and CAR persistence (2020-03-03),

12. 10501519 - Use of the CD2 signaling domain in second-generation chimeric antigen receptors (2019-12-10),

13. 10329355 - Compositions and methods for targeting stromal cells for the treatment of cancer (2019-06-25),

14. 10308717 - Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor (2019-06-04),

15. 10221245 - Treatment of cancer using humanized anti-CD19 chimeric antigen receptor (2019-03-05),

Title: Unveiling the Pioneering Work of Inventor John Scholler

Introduction:

John Scholler, a distinguished inventor based in Narberth, PA, has made significant contributions to the field of cancer treatment through his innovative patented technologies.

Latest Patents:

1. "Use of ICOS-based cars to enhance antitumor activity and car persistence": This patent focuses on administering genetically modified Th17 cells to treat cancer by expressing a CAR with specific domains for effective treatment.

2. "Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor": This patent reveals compositions and methods for combating diseases associated with EGFRvIII expression by using chimeric antigen receptors and genetically modified T cells.

Career Highlights:

With an impressive portfolio of 19 patents, John Scholler has been a driving force in advancing cancer treatment methodologies. He has made notable contributions during his tenure at the University of Pennsylvania and Novartis AG.

Collaborations:

John Scholler has collaborated with esteemed colleagues such as Carl H June and Jennifer Brogdon, enhancing the interdisciplinary nature of his research and fostering innovative solutions in the field of oncology.

Conclusion:

Inventor John Scholler's groundbreaking work exemplifies a commitment to revolutionizing cancer treatment through cutting-edge technologies. His patents and collaborations underscore his dedication to improving patient outcomes and advancing the boundaries of medical science.

This text is generated by artificial intelligence and may not be accurate.